FDA Awards Priority Review Voucher to NULIBRY for Rare Pediatric Disease Product

Summary

The FDA has issued a priority review voucher to NULIBRY (fosdenopterin), a rare pediatric disease product, following a review of its application, as required by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Food and Drug Administration Safety and Innovation Act (FDASIA).